JP7795181B2 - インターロイキン－１８バリアントとその利用法 - Google Patents

インターロイキン－１８バリアントとその利用法

Info

Publication number
JP7795181B2
JP7795181B2 JP2020513648A JP2020513648A JP7795181B2 JP 7795181 B2 JP7795181 B2 JP 7795181B2 JP 2020513648 A JP2020513648 A JP 2020513648A JP 2020513648 A JP2020513648 A JP 2020513648A JP 7795181 B2 JP7795181 B2 JP 7795181B2
Authority
JP
Japan
Prior art keywords
seq
variant
md2d
variant polypeptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020513648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533301A5 (https=
JP2020533301A (ja
Inventor
リング アーロン
チョウ ティン
フィッシャー スザンヌ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of JP2020533301A publication Critical patent/JP2020533301A/ja
Publication of JP2020533301A5 publication Critical patent/JP2020533301A5/ja
Priority to JP2023133442A priority Critical patent/JP2023157959A/ja
Application granted granted Critical
Publication of JP7795181B2 publication Critical patent/JP7795181B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2020513648A 2017-09-06 2018-09-06 インターロイキン－１８バリアントとその利用法 Active JP7795181B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023133442A JP2023157959A (ja) 2017-09-06 2023-08-18 インターロイキン－１８バリアントとその利用法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762554605P 2017-09-06 2017-09-06
US62/554,605 2017-09-06
US201862652279P 2018-04-03 2018-04-03
US62/652,279 2018-04-03
PCT/US2018/049648 WO2019051015A1 (en) 2017-09-06 2018-09-06 VARIANTS OF INTERLEUKIN-18 AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023133442A Division JP2023157959A (ja) 2017-09-06 2023-08-18 インターロイキン－１８バリアントとその利用法

Publications (3)

Publication Number Publication Date
JP2020533301A JP2020533301A (ja) 2020-11-19
JP2020533301A5 JP2020533301A5 (https=) 2021-10-14
JP7795181B2 true JP7795181B2 (ja) 2026-01-07

Family

ID=65517760

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020513648A Active JP7795181B2 (ja) 2017-09-06 2018-09-06 インターロイキン－１８バリアントとその利用法
JP2023133442A Pending JP2023157959A (ja) 2017-09-06 2023-08-18 インターロイキン－１８バリアントとその利用法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023133442A Pending JP2023157959A (ja) 2017-09-06 2023-08-18 インターロイキン－１８バリアントとその利用法

Country Status (13)

Country Link
US (6) US20190070262A1 (https=)
EP (1) EP3678681A4 (https=)
JP (2) JP7795181B2 (https=)
KR (1) KR20200066623A (https=)
CN (1) CN111315395A (https=)
AU (2) AU2018330444B2 (https=)
BR (1) BR112020004389A2 (https=)
CA (1) CA3080492A1 (https=)
IL (2) IL272635B2 (https=)
MX (1) MX2020002542A (https=)
SG (1) SG11202001384TA (https=)
WO (1) WO2019051015A1 (https=)
ZA (1) ZA202307212B (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12029778B2 (en) 2019-05-13 2024-07-09 Yale University Interleukin-18 mimics and methods of use
WO2021231447A1 (en) * 2020-05-12 2021-11-18 Regeneron Pharmaceuticals, Inc. Novel il10 agonists and methods of use thereof
CA3189327A1 (en) * 2020-08-19 2022-02-24 Vijaya Raghavan PATTABIRAMAN Modified il-18 polypeptides and uses thereof
JP2023550545A (ja) * 2020-11-02 2023-12-01 シムハ・アイエル－１８・インコーポレイテッド インターロイキン－１８バリアントおよび使用の方法
JP7812094B2 (ja) * 2021-02-10 2026-02-09 国立大学法人 長崎大学 新規ヒトインターロイキン－１８変異体及びその用途
US20230146665A1 (en) 2021-07-27 2023-05-11 Xencor, Inc. Il-18-fc fusion proteins
JP7849832B2 (ja) 2021-08-06 2026-04-22 国立大学法人 長崎大学 がんの治療剤
WO2023114829A1 (en) 2021-12-15 2023-06-22 Genentech, Inc. Stabilized il-18 polypeptides and uses thereof
WO2023118497A1 (en) * 2021-12-22 2023-06-29 Pieris Pharmaceuticals Gmbh Novel il-18 variants
US20230263831A1 (en) * 2022-02-23 2023-08-24 Fred Hutchinson Cancer Center Methods for enhancing anti-tumor activity of exhausted t cells
AU2023226512A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Immune antigen specific il-18 immunocytokines and uses thereof
CA3244053A1 (en) * 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag MODIFIED IL-18 POLYPEPTIDES
AU2023226005A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
WO2023215834A1 (en) * 2022-05-05 2023-11-09 Hospital Espanol Auxilio Mutuo De Puerto Rico, Inc. Methods for treating bladder cancer
AU2023320522A1 (en) * 2022-08-05 2025-01-23 Fuse Biotherapeutics Inc. Il-18 fusion proteins and methods of producing il-18
WO2024044780A1 (en) * 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof
US20260092093A1 (en) * 2022-09-06 2026-04-02 TJ Biopharma (Shanghai) Co., Ltd. Il-18 variant polypeptides
WO2024086852A1 (en) * 2022-10-21 2024-04-25 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
WO2024102693A2 (en) 2022-11-07 2024-05-16 Xencor, Inc. Il-18-fc fusion proteins
CN118141897A (zh) 2022-12-07 2024-06-07 广州威溶特医药科技有限公司 Dr-18和溶瘤痘苗病毒在制备抗肿瘤药物中的应用
TW202430560A (zh) * 2023-01-06 2024-08-01 美商拉森醫療公司 抗ｉｌ－１８ｂｐ抗體
WO2024148232A2 (en) * 2023-01-06 2024-07-11 Alector Llc Anti-il18 binding protein antibodies and methods of use thereof
KR20250133728A (ko) 2023-01-06 2025-09-08 라센 테라퓨틱스, 인코포레이티드 항-il-18bp 항체
WO2024158840A2 (en) * 2023-01-24 2024-08-02 Simcha IL-18, Inc. Methods and compositions for combination therapy
CN121666402A (zh) * 2023-06-09 2026-03-13 默克专利股份公司 Il-18模拟物
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
WO2025015103A1 (en) * 2023-07-10 2025-01-16 The Children's Hospital Of Philadelphia Methods for modulating activity of il-18 for treatment of cd4+ t cell mediated autoimmunity and immunopathology
WO2025041102A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Targeted immune activation with il-18 immunocytokines
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
WO2025041097A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof
WO2025068413A1 (en) 2023-09-28 2025-04-03 Prokarium Limited Interleukin 18 variants
WO2025085447A1 (en) 2023-10-17 2025-04-24 Xencor, Inc. Pd-1 targeted il18-fc fusion proteins
CN120093897A (zh) * 2023-12-04 2025-06-06 广州威溶特医药科技有限公司 Dr-18和单纯疱疹病毒在制备抗肿瘤药物中的应用
CN120189493A (zh) 2023-12-22 2025-06-24 广州威溶特医药科技有限公司 Dr-18和m1病毒在制备抗肿瘤药物中的应用
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same
WO2025151273A1 (en) * 2024-01-08 2025-07-17 Adimab, Llc Il-18 polypeptides and uses thereof
WO2025185694A1 (en) * 2024-03-06 2025-09-12 TJ Biopharma (Shanghai) Co., Ltd. Constructs comprising il-18 components and uses thereof
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2025251226A1 (en) 2024-06-05 2025-12-11 Nuwacell Biotechnologies Co., Ltd. Use of interleukin-21 and interleukin-15 for enhancing serial killing of natural killer cell for cell therapy against target cell
WO2026083296A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004530432A (ja) 2001-03-08 2004-10-07 アレス・トレーディング・ソシエテ・アノニム インターロイキン−１８変異体、その産生および使用
JP2011105737A (ja) 2003-04-15 2011-06-02 Glaxosmithkline Llc ヒトｉｌ−１８を含むコンジュゲートおよびその置換変異体
WO2017103088A1 (en) 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
EP0816499A3 (en) * 1996-06-27 1999-10-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma
US6790442B1 (en) 1996-06-27 2004-09-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomic DNA encoding a polypeptide capable of inducing the production of interferon-γ
JP4024366B2 (ja) 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
JP3955352B2 (ja) 1997-02-25 2007-08-08 株式会社林原生物化学研究所 破骨細胞形成阻害剤
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
JP2001266941A (ja) 2000-03-17 2001-09-28 Sony Corp ゲル電解質電池の製造方法
CN1457258A (zh) * 2000-06-02 2003-11-19 史密丝克莱恩比彻姆公司 用il－18和il－18组合物治疗病毒性疾病的方法
PL366134A1 (en) 2000-06-15 2005-01-24 Smithkline Beecham Corporation Method for preparing a physiologically active il-18 polypeptide
US6818444B2 (en) 2000-08-04 2004-11-16 Heska Corporation Canine and feline proteins, nucleic acid molecules and uses thereof
DE60238532D1 (de) 2001-05-04 2011-01-20 Cornell Res Foundation Inc Schnell spaltbares sumofusionsprotein-expressionssystem für schwer zu exprimierende proteine
WO2003031569A2 (en) 2001-10-10 2003-04-17 Centocor, Inc. Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid
US20040023336A1 (en) 2001-10-26 2004-02-05 Heavner George A. Mut-IL-18 or Mut-IL-18R proteins, antibodies, compositions, methods and uses
US6800479B2 (en) 2001-12-11 2004-10-05 Samyang Genex Corporation Recombinant adenoviruses expressing interleukin-18 protein and gene therapy using them
US7220576B2 (en) 2002-01-07 2007-05-22 Lifesensors, Inc. Methods and compositions for protein expression and purification
CA2472477C (en) 2002-01-07 2012-03-20 Lifesensors, Inc. Methods and compositions for protein expression and purification
US7253260B2 (en) 2002-04-17 2007-08-07 Smithkline Beecham Corporation Human IL-18 crystal structure
WO2004002519A1 (en) * 2002-06-27 2004-01-08 Smithkline Beecham Corporation Methods of treating or preventing ibd with il-18
AU2003299919B2 (en) * 2002-10-08 2009-08-06 Ares Trading S.A. The use of cytokine able to bind IL-18BP and of inhibiting the activity of a second cytokine
US20080076708A1 (en) * 2003-05-13 2008-03-27 Valter Altarocca Active Variants of the Il-18 Binding Protein and Medical Uses Thereof
AU2004254600A1 (en) 2003-06-26 2005-01-13 Lifesensors, Inc. Methods and compositions for enhanced protein expression and purification
ATE500267T1 (de) * 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
DE602004031341D1 (de) 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
WO2005075648A1 (en) * 2004-01-28 2005-08-18 Gifu University Interleukin-18 mutant proteins
AU2005277404A1 (en) 2004-08-20 2006-03-02 Smithkline Beecham Corporation Methods of healing wounds by administering human IL-18
EP1836214A4 (en) 2004-12-30 2009-01-21 Lifesensors Inc COMPOSITIONS, METHODS, AND KITS FOR IMPROVING PROTEIN EXPRESSION, SOLUBILITY, AND ISOLATION
EP2059253A4 (en) 2006-09-14 2011-09-14 Univ Pennsylvania MODULATION OF T LYMPHOCYTES REGULATORS BY HUMAN IL-18
JP5469786B2 (ja) 2006-12-29 2014-04-16 ライフセンサーズ、インク． タンパク質の発現増強および精製の方法および組成
KR101867606B1 (ko) 2007-11-07 2018-06-18 제넨테크, 인크. 미생물 질환의 치료를 위한 조성물 및 방법
WO2009107458A1 (ja) 2008-02-27 2009-09-03 シャープ株式会社 照明装置、表示装置及びテレビ受信装置
US8034910B2 (en) 2008-05-06 2011-10-11 Academia Sinica, Taiwan SUMO fusion protein expression system for producing native proteins
CN101993495B (zh) 2009-08-12 2013-07-24 上海近岸科技有限公司 一种蛋白质混合物及其制备方法
US9316417B2 (en) 2012-06-29 2016-04-19 Sunpower Corporation Framing system for mounting solar collecting devices
KR20150037959A (ko) 2012-08-02 2015-04-08 에프. 호프만-라 로슈 아게 단량체 및 다량체 분자의 제조 방법 및 이의 용도
US9376489B2 (en) * 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
US10646548B2 (en) 2013-10-08 2020-05-12 Georgia State University Research Foundation, Inc. Compositions including IL-18 and IL-22 and their use in anti-viral therapies
US10882905B2 (en) 2015-03-05 2021-01-05 Ab2 Bio Sa IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases
CN108064176A (zh) 2015-04-22 2018-05-22 库瑞瓦格股份公司 用于治疗肿瘤疾病的含有rna的组合物
AU2017213659B2 (en) 2016-02-05 2024-04-18 Washington University Compositions and methods for targeted cytokine delivery
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
ITUA20161992A1 (it) 2016-03-24 2017-09-24 Plico Biotech Inc Sumo e suoi utilizzi
CA3032838A1 (en) 2016-08-04 2018-02-08 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
WO2018064611A1 (en) 2016-09-30 2018-04-05 Baylor College Of Medicine Antibody based gene therapy with tissue-directed expression
TWI591177B (zh) 2016-10-27 2017-07-11 中化合成生技股份有限公司 一種胰高血糖素胜肽－２（ｇｌｐ－２）類似物的製備方法
KR102867975B1 (ko) 2017-03-06 2025-10-14 알토 바이오사이언스 엘엘씨 Il-12 및 il-18로의 il-15-기반 융합
JP2020530280A (ja) 2017-07-03 2020-10-22 トルク セラピューティクス， インコーポレイテッド 免疫刺激性融合分子およびその使用
EP3788150A4 (en) 2018-05-04 2022-01-26 Sigma-Aldrich Co. LLC PRODUCTION OF RECOMBINANT PROTEINS WITH REDUCED LEVELS OF HOST CELL PROTEINS
EP3843788A1 (en) 2018-08-30 2021-07-07 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
CN120365435A (zh) 2018-08-30 2025-07-25 免疫生物公司 单链嵌合多肽和多链嵌合多肽以及其用途
CN112996805A (zh) 2018-08-30 2021-06-18 Hcw生物科技公司 多链嵌合多肽和其用途
US20220073908A1 (en) 2019-01-04 2022-03-10 Repertoire Immune Medicines, Inc. Methods of producing high diversity peptide libraries and promoting protein folding
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
US20220226464A1 (en) 2019-05-28 2022-07-21 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
EP3976068A4 (en) 2019-05-31 2023-08-09 Children's National Medical Center CYTOKINE COCKTAILS FOR SELECTIVE T-LYMPHOCYTE SUBSET EXPANSION
AU2020327671A1 (en) 2019-08-13 2022-03-03 King's College London Immunoresponsive cells armoured with spatiotemporally restricted activity of cytokines of the IL-1 superfamily
CA3154771A1 (en) 2019-10-09 2021-04-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cytotoxic t cell resistant tumors
US12551530B2 (en) 2020-08-14 2026-02-17 Kite Pharma, Inc. Immune cell function
CA3189327A1 (en) 2020-08-19 2022-02-24 Vijaya Raghavan PATTABIRAMAN Modified il-18 polypeptides and uses thereof
JP2023550545A (ja) 2020-11-02 2023-12-01 シムハ・アイエル－１８・インコーポレイテッド インターロイキン－１８バリアントおよび使用の方法
US20240197880A1 (en) 2021-04-30 2024-06-20 Cellectis S.A. New anti-muc1 cars and gene edited immune cells for solid tumors cancer immunotherapy
US20250281638A1 (en) 2021-06-10 2025-09-11 Chimera Bioengineering, Inc. Compositions and Methods for Activating Natural Killer Cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004530432A (ja) 2001-03-08 2004-10-07 アレス・トレーディング・ソシエテ・アノニム インターロイキン−１８変異体、その産生および使用
JP2011105737A (ja) 2003-04-15 2011-06-02 Glaxosmithkline Llc ヒトｉｌ−１８を含むコンジュゲートおよびその置換変異体
WO2017103088A1 (en) 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Proc Natl Acad Sci, 2000年, 97(3):1190-5
Proc Natl Acad Sci, 2001年, 98(6):3304-9

Also Published As

Publication number Publication date
IL305370A (en) 2023-10-01
JP2023157959A (ja) 2023-10-26
BR112020004389A2 (pt) 2020-09-08
US20230241172A1 (en) 2023-08-03
IL272635B2 (en) 2024-02-01
US12403180B2 (en) 2025-09-02
CA3080492A1 (en) 2019-03-14
US20240325494A1 (en) 2024-10-03
RU2020112538A (ru) 2021-10-06
EP3678681A1 (en) 2020-07-15
MX2020002542A (es) 2020-07-20
SG11202001384TA (en) 2020-03-30
EP3678681A4 (en) 2021-07-14
US12343379B2 (en) 2025-07-01
WO2019051015A1 (en) 2019-03-14
AU2018330444B2 (en) 2023-08-17
US20230321192A1 (en) 2023-10-12
IL272635A (en) 2020-03-31
US12594325B2 (en) 2026-04-07
IL272635B1 (en) 2023-10-01
JP2020533301A (ja) 2020-11-19
US20230355714A1 (en) 2023-11-09
KR20200066623A (ko) 2020-06-10
CN111315395A (zh) 2020-06-19
RU2020112538A3 (https=) 2022-04-04
AU2023266285A1 (en) 2024-01-25
US20190070262A1 (en) 2019-03-07
AU2018330444A1 (en) 2020-04-23
ZA202307212B (en) 2024-10-30
US20250057918A1 (en) 2025-02-20

Similar Documents

Publication Publication Date Title
JP7795181B2 (ja) インターロイキン－１８バリアントとその利用法
US12582701B2 (en) Interleukin-18 variants and methods of use
US12029778B2 (en) Interleukin-18 mimics and methods of use
CN119497718A (zh) 三特异性抗体及其用途
US20240342246A1 (en) Interleukin-12 variants and methods of use
RU2797536C2 (ru) Варианты интерлейкина-18 и способы их применения
HK40100300A (zh) 白介素-18变体和使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210903

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230818

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230927

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251021

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251212

R150 Certificate of patent or registration of utility model

Ref document number: 7795181

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150